Bayer profits up 11.5 percent on new drugs

April 25, 2013

German chemical and pharmaceutical company Bayer AG said Thursday that its net profit rose 11.5 percent in the first quarter as new drugs, led by blood thinner Xarelto, boosted sales.

The company also saw stronger demand in emerging markets—which helped overcome weaker business in Europe, which is in a recession.

Overall, Bayer said its net income rose to 1.16 billion euros ($1.51 billion) from 1.04 billion in the same quarter a year earlier and that revenue rose 2.1 percent to 10.2 billion euros.

The standout performance was Xarelto, which more than tripled sales to 155 million euros. The drug's uses include preventing potentially life threatening blood clots that can form in people who have had hip or .

The company said it also had strong results from cancer drug Stivarga and from Eylea, which is used to treat the eye disease macular degeneration.

Elsewhere, Bayer said health care sales rose 7.6 percent in Asia and 4.5 percent in North America, outpacing Europe at 1.9 percent.

The company also saw continuing strong demand for its farm products such as seeds and crop protection chemicals, and that despite a late start to the growing season in the . That division raised its sales by 5.9 percent thanks to persistently high price levels for agricultural commodities.

The company stood by its forecast for a high-single digit percentage increase in profits and an increase in sales of between 4 percent and 5 percent.

Explore further: Lawsuit charges weigh on Bayer profits again

shares

Related Stories

Lawsuit charges weigh on Bayer profits again

February 28, 2013
(AP)—Charges for lawsuits over its birth control pills weighed on Bayer AG's earnings once again during the fourth quarter of 2012.

Merck Q4 net profit more than doubles

March 7, 2013
Merck KGaA saw its profit more than double in the fourth quarter as the German pharmaceutical company benefited from higher prices for its Rebif multiple sclerosis drug and reaped rewards from its ongoing restructuring.

Roche sales up 5 percent amid rush for Tamiflu, cancer drugs

April 11, 2013
Swiss drug giant Roche said Thursday that heightened demand for its Tamiflu drug amid a severe flu season, as well as for its cancer medicines had sent its first-quarter sales up five percent, beating analyst expectations.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.